A Study of a Candidate COVID-19 Vaccine (COV003)

Inclusion Criteria:

- Adults from 18 to 55 years of age

- Adults aged 56-69 years old (after review of safety data by DSMB in this age group in
the UK trial)

- Adults aged 70 and above years old (after review of safety data by DSMB in this age
group in the UK trial)

- Able and willing (in the Investigator's opinion) to fulfill all study requirements;

- Health professionals and adults at high risk of exposure to SARS-CoV-2, as defined in
section 5.2 of this protocol;

- Serology with SARS-CoV-2 negative IgG antibodies; This inclusion criteria does not
apply to participants enrolled from version 4.0 of the protocol onwards.

- Willing to allow investigators to discuss the participant's clinical history with
their GP/personal physician and access medical records relevant to the study
procedures

- Only for women of childbearing age willing to practice continuous effective birth
control (see below) during the study, and a negative pregnancy test on the screening
and vaccination day(s);

- Consent to abstain from blood donation during the course of the study;

- Provide informed consent in writing

Exclusion Criteria:

- Participation in trials of prophylactic drugs for COVID-19 during the course of the
study; Note: Participation in COVID-19 treatment trials is permitted in case of
hospitalization due to COVID-19, after confirmation of positive PCR. The study team
should be informed as soon as possible. Participants with COVID-19 not hospitalized
with positive PCR results for COVID-19 may be medicated according to standard clinical
practice.

- Participation in SARS-CoV-2 serological research where participants are informed of
their serological status during the course of the study;

- Planned receipt of any vaccine (authorized or investigational), within 30 days before
and after vaccination;

- Prior receipt of an investigational vaccine or authorized with the possibility of
impacting the interpretation of the study data (for example, vaccines vectorized by
Adenovirus, any vaccines against coronavirus);

- Administration of immunoglobulins and/or any blood products in the three months prior
to the planned administration of the candidate vaccine;

- Any confirmed or suspected immunosuppressive or immunodeficiency state; asplenia;
severe recurrent infections and chronic use (more than 14 days) of immunosuppressive
medication in the last 6 months, except for topical steroids or short-term oral
steroids (cycle lasting ≤14 days);

- History of allergic disease or reactions possibly exacerbated by any component of
ChAdOx1 nCoV-19 or MenACWY or paracetamol;

- Any history of angioedema;

- Any history of anaphylaxis;

- Pregnancy, lactation or willingness/intention to become pregnant during the study;

- Current diagnosis or treatment for cancer (except basal cell carcinoma of the skin and
cervical carcinoma in situ);

- History of severe psychiatric illness that possibly affects your participation in the
study;

- Hemorrhagic disorder (for example, factor deficiency, coagulopathy or platelet
disorder), or a previous history of significant bleeding or bruising after IM
injections or venipuncture;

- Current suspected or known dependence on alcohol or drugs;

- Severe and/or uncontrolled cardiovascular diseases, respiratory diseases,
gastrointestinal diseases, liver disease, kidney disease, endocrine disorder, and
neurological disease (mild/moderate well-controlled comorbidities are allowed);

- History of COVID-19 confirmed by laboratory;

- Seropositive for antibodies to SARS-CoV-2 before recruitment; This exclusion criteria
does not apply to participants enrolled from version 4.0 of the protocol onwards

- Continued use of anticoagulants, such as coumarins and related anticoagulants (for
example, warfarin) or new oral anticoagulants (for example, apixaban, rivaroxaban,
dabigatran and edoxaban);

- Any other significant illness, disorder or finding that may significantly increase the
risk for the participant, affect his/her ability to participate in the study or impair
the interpretation of the study data.

Re-vaccination exclusion criteria (two-dose groups only)

- Anaphylactic reaction following administration of vaccine

- Pregnancy